Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods. We used the commonly accepted PICo(S) questionnaire with the following specifics: the population – patients with R/R MS...
Main Authors: | D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2018-11-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/261 |
Similar Items
-
The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
by: Mohammad Z.I. Asha, et al.
Published: (2021-12-01) -
Ocrelizumab in treatment of primary-progressive multiple sclerosis: systematic review
by: D. L. Klabukova, et al.
Published: (2018-07-01) -
Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01) -
The experience of using ocrelizumab in routine practice
by: E. V. Popova, et al.
Published: (2020-03-01) -
The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
by: Şenay Yıldız Çelik
Published: (2017-09-01)